For example, for the classification of gliomas and glioneuronal and neuronal tumors, BRAF V600E is available, but we still lack molecular tools such as BRAF fusions, fusions between MYB or MYBL1 and a partner gene necessary for the diagnosis of MYB- or MYBL1 altered diffuse astrocytoma, as well as deletions and amplifications at the MYB locus on 6q23.3 for the diagnosis of angiocentric glioma and MAPK pathway-activating abnormalities needed in the diagnosis of both polymorphous low-grade neuroepithelial tumor of the young and diffuse low-grade glioma, MAPK pathway-altered (1). This evidence concerns the gene MYBL1 and central nervous system cancer.